CN105263926B - 苯并噻吩化合物 - Google Patents

苯并噻吩化合物 Download PDF

Info

Publication number
CN105263926B
CN105263926B CN201480031630.3A CN201480031630A CN105263926B CN 105263926 B CN105263926 B CN 105263926B CN 201480031630 A CN201480031630 A CN 201480031630A CN 105263926 B CN105263926 B CN 105263926B
Authority
CN
China
Prior art keywords
compound
salt
methyl
pain
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480031630.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263926A (zh
Inventor
石原司
生贝和弘
栗胁生实
久道弘幸
竹下畅昭
武泽龙
武泽龙一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN105263926A publication Critical patent/CN105263926A/zh
Application granted granted Critical
Publication of CN105263926B publication Critical patent/CN105263926B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480031630.3A 2013-06-06 2014-06-06 苯并噻吩化合物 Expired - Fee Related CN105263926B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-119416 2013-06-06
JP2013119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (2)

Publication Number Publication Date
CN105263926A CN105263926A (zh) 2016-01-20
CN105263926B true CN105263926B (zh) 2018-05-11

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480031630.3A Expired - Fee Related CN105263926B (zh) 2013-06-06 2014-06-06 苯并噻吩化合物

Country Status (32)

Country Link
US (2) US8981119B2 (2)
EP (1) EP3006443B1 (2)
JP (1) JP6314978B2 (2)
KR (1) KR102253721B1 (2)
CN (1) CN105263926B (2)
AR (1) AR096544A1 (2)
AU (1) AU2014275768B2 (2)
BR (1) BR112015030533B1 (2)
CA (1) CA2914606C (2)
CY (1) CY1120341T1 (2)
DK (1) DK3006443T3 (2)
ES (1) ES2671818T3 (2)
HR (1) HRP20180722T1 (2)
HU (1) HUE038920T2 (2)
IL (1) IL242800B (2)
LT (1) LT3006443T (2)
MX (1) MX2015016743A (2)
MY (1) MY199155A (2)
NO (1) NO3006443T3 (2)
PH (1) PH12015502637B1 (2)
PL (1) PL3006443T3 (2)
PT (1) PT3006443T (2)
RS (1) RS57250B1 (2)
RU (1) RU2667507C2 (2)
SG (1) SG11201509989VA (2)
SI (1) SI3006443T1 (2)
SM (1) SMT201800306T1 (2)
TR (1) TR201808724T4 (2)
TW (1) TWI624466B (2)
UA (1) UA117484C2 (2)
WO (1) WO2014196644A1 (2)
ZA (1) ZA201508866B (2)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144183A (zh) * 2019-07-23 2022-03-04 阿斯特拉斯制药全球发展有限公司 治疗与疼痛相关的睡眠障碍的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
US20040116405A1 (en) 2001-02-06 2004-06-17 Brian Cox Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
CN1852906A (zh) 2003-07-15 2006-10-25 史密丝克莱恩比彻姆公司 新化合物
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
WO2009035671A1 (en) * 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
EP2358750B1 (en) 2008-11-10 2017-01-11 Boehringer Ingelheim International GmbH Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Also Published As

Publication number Publication date
MX2015016743A (es) 2016-03-21
PL3006443T3 (pl) 2018-09-28
EP3006443A1 (en) 2016-04-13
NO3006443T3 (2) 2018-09-22
US8981119B2 (en) 2015-03-17
LT3006443T (lt) 2018-07-10
IL242800B (en) 2019-06-30
UA117484C2 (uk) 2018-08-10
MY199155A (en) 2023-10-18
AU2014275768A1 (en) 2015-12-17
AR096544A1 (es) 2016-01-13
TW201536775A (zh) 2015-10-01
BR112015030533B1 (pt) 2023-02-28
RU2667507C2 (ru) 2018-09-21
US20150133433A1 (en) 2015-05-14
WO2014196644A1 (ja) 2014-12-11
US9399038B2 (en) 2016-07-26
TR201808724T4 (tr) 2018-07-23
CA2914606A1 (en) 2014-12-11
US20140364421A1 (en) 2014-12-11
ES2671818T3 (es) 2018-06-08
PH12015502637B1 (en) 2019-02-08
HUE038920T2 (hu) 2018-12-28
ZA201508866B (en) 2017-11-29
HK1215570A1 (zh) 2016-09-02
AU2014275768B2 (en) 2017-12-14
TWI624466B (zh) 2018-05-21
HRP20180722T1 (hr) 2018-06-15
KR102253721B1 (ko) 2021-05-18
IL242800A0 (en) 2016-02-01
PT3006443T (pt) 2018-06-07
CN105263926A (zh) 2016-01-20
RU2015152150A (ru) 2017-07-13
RS57250B1 (sr) 2018-07-31
DK3006443T3 (en) 2018-06-25
CA2914606C (en) 2021-03-23
SMT201800306T1 (it) 2018-07-17
CY1120341T1 (el) 2019-07-10
EP3006443A4 (en) 2016-12-21
PH12015502637A1 (en) 2016-03-07
EP3006443B1 (en) 2018-04-25
SG11201509989VA (en) 2016-01-28
KR20160015281A (ko) 2016-02-12
SI3006443T1 (en) 2018-08-31
JP6314978B2 (ja) 2018-04-25
BR112015030533A2 (pt) 2020-10-20
JPWO2014196644A1 (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
JP6437060B2 (ja) 縮合環類似体の抗線維症剤
JP5408434B2 (ja) アミド化合物
TW201910306A (zh) Nlrp3發炎體之選擇性抑制劑
TW200530195A (en) Benzimidazole derivatives: preparation and pharmaceutical applications
CN105793236B (zh) 二甲基苯甲酸化合物
AU2012337781A1 (en) Dihydroxy aromatic heterocyclic compound
TW200838526A (en) Carboxylic acid derivatives
CN105228982A (zh) 用于治疗过度增殖性病症的3-乙酰基氨基-1-(苯基-杂芳基-氨基羰基或苯基-杂芳基-羰基氨基)苯衍生物
BR112014010169B1 (pt) Compostos de derivado n-tienilbenzamida substituída com aminoalquil, composição contendo os ditos compostos e uso dos mesmos para prevenir ou tratar hiperfosfatemia
KR20090122931A (ko) 오르니틴 유도체
WO2011034078A1 (ja) グリシン化合物
JP2021513982A (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法
CN112020494A (zh) 用作tlr2信号转导调节剂的化合物
CN107459476B (zh) 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
CN105263926B (zh) 苯并噻吩化合物
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
CN106573928B (zh) 2-氨基噻唑衍生物或其盐
WO2022068815A1 (zh) Fxr小分子激动剂及其制备方法和用途
HK1215570B (en) Bensothiophene compound
HK1221215B (zh) 4-炔基咪唑衍生物和含有其作为有效成分的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215570

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180511

CF01 Termination of patent right due to non-payment of annual fee